Biming He

Dr. Biming He

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Urology
Verified
Journal Article
Open access
HWHaifeng Wang
Haifeng Wang
HLHengzhi Lin
Hengzhi Lin
BHBiming He
Biming He
XGXiaodan Guo
Xiaodan Guo
YZYi Zhou
Yi Zhou
YSYinghao Sun
Yinghao Sun
To develop and validate a novel perineal nerve block approach for transperineal prostate biopsy. Five adult male cadavers were dissected to delineate the superficial and deep branches of the perineal nerve. Afterwards, 90 out of 115 patients were selected and randomly assigned to receive periprostatic, periapical triangle (PAT), or branches of perineal nerve (BPN) block. The primary outcome was the maximal pain intensity associated with transperineal prostate biopsy, which was assessed by the 10-point VAS. The secondary outcomes included the number of biopsy with VAS of >=4 in each biopsy procedure, and the incidences of complications. On the horizontal line of the upper anal border, the locations of the superficial branch of perineal nerve on the left and right sides were 1.87±0.05 cm and 1.86±0.06 cm, respectively; and the deep branch were 2.15±0.07 cm and 2.16±0.06 cm, respectively, from the midline, and lied between the deep layer of superficial fascia and prostate capsule. The number of cases finally enrolled in data analysis in periprostatic block, PAT block, and BPN block groups were 26, 27, and 30, respectively. The maximal pain intensities were 3.4 (3.1-3.7), 3.3 (3.0-3.6), and 1.8 (1.5-2.2) in the three groups, respectively, and the numbers of biopsy with the pain intensity of >=4 were 4.0 (3.2-4.9), 4.2 (3.3-5.2), and 0.7 (0.1-1.2), respectively. There were 4, 3 and 4 cases developing hematuria, and 1, 1 and 2 burdened with urine retention after biopsy in the three groups, respectively. Collectively, BPN block is a safe, effective and repeatable local anesthesia approach for transperineal prostate biopsy.

17 December 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
BHBiming He
Biming He
ZSZhen-Kai Shi
Zhen-Kai Shi
HLHu-Sheng Li
Hu-Sheng Li
HLHeng-Zhi Lin
Heng-Zhi Lin
QYQing-Song Yang
Qing-Song Yang
HWHai-Feng Wang
Hai-Feng Wang

1 August 2023 in International Journal of Surgery
Verified
Journal Article
Open access
BHBiming He
Biming He
QYQiwei Yang
Qiwei Yang
ZSZhen-Kai Shi
Zhen-Kai Shi
TJTang-Rao Ji
Tang-Rao Ji
SWShuai-Dong Wang
Shuai-Dong Wang
HWHai-Feng Wang
Hai-Feng Wang
Background: APROPOS was a multicentre, randomized, blinded trial focus on investigating the perineal nerve block versus the periprostatic block in pain control for men undergoing a transperineal prostate biopsy. In the analysis reported here, the authors aimed to evaluate the association of biopsy core count and location with pain outcomes in patients undergoing a transperineal prostate biopsy under local anesthesia. Methods: APROPOS was performed at six medical centers in China. Patients with suspected prostate cancer were randomized to receive either a perineal nerve block or a periprostatic block (1:1), followed by a transperineal prostate biopsy. The secondary analysis outcomes were the worst pain experienced during the prostate biopsy and postbiopsy pain at 1,6, and 24 h. Results: Between 12 August 2020 and 20 July 2022, a total of 192 patients were randomized in the original trial, and 188 were involved in this analysis, with 94 patients per group. Participants had a median (IQR) age of 68 (63–72) and a median (IQR) prostate volume of 42.51 (30.04–62.84). The patient population had a median (IQR) number of biopsy cores of 15 (12–17.50), and 26.06% of patients had a biopsy cores count of more than 15. After adjusting the baseline characteristics, the number of biopsy cores was associated with the worst pain during the biopsy procedure in both the perineal nerve block group (β 0.19, 95% CI: 0.12–0.26, P<0.001) and the periprostatic block group (β 0.16, 95% CI: 0.07–0.24, P<0.001). A similar association was also evident for the postbiopsy pain at 1, 6, and 24 h. A lesser degree of pain in both groups at any time (r range −0.57 to −0.01 for both groups) was associated with biopsy cores from the peripheral zone of the middle gland, while other locations were associated with a higher degree of pain. In addition, the location of the biopsy core had less of an effect on pain during the biopsy (r range −0.01–0.25 for both groups) than it did on postbiopsy pain (r range −0.57–0.60 for both groups). Conclusions: In this secondary analysis of a randomized trial, biopsy core count and location were associated with pain in patients undergoing a transperineal prostate biopsy under local anesthesia. These results may be helpful for making clinical decisions about the anesthetic approach for scheduled transperineal prostate biopsies.

21 September 2023 in International Journal of Surgery
Verified
Journal Article
Open access
ZQZiyun Qiao
Ziyun Qiao
SWShuaidong Wang
Shuaidong Wang
HWHaiyan Wang
Haiyan Wang
BHBiming He
Biming He
ZSZhenkai Shi
Zhenkai Shi
HWHaifeng Wang
Haifeng Wang
Background: Radical prostatectomy with pelvic lymph node dissection for the treatment of high-risk localized prostate cancer (PCa) results in long-term benefits in selected patients. But insufficient sensitivity of conventional examinations which are pelvic MRI and bone scan, limits the diagnosis of bone and lymph node metastasis of PCa. This affects the surgical management strategy of a large number of patients. The purpose of this study was to investigate whether 18F-prostate-specific membrane antigen (PSMA) PET-MRI could improve the clinical detection of PCa metastases compared with the conventional pelvic MRI plus bone scan. Materials and methods: From April 2020 to April 2023, we prospectively enroled 472 patients with histologically proven PCa in our centre, and 120 patients underwent 18F-PSMA PET-MRI, multiparametric MRI, and bone scan before laparoscopic radical prostatectomy plus lymph node dissection. The accuracy of imaging results in detecting lymph node and bone metastatic lesions was compared between PSMA PET-MRI and MRI plus bone scan. Results: In diagnosing lymph node metastasis, PSMA PET-MRI had an area under the curve (AUC) of 0.844 (95% CI: 0.738–0.949, P < 0.001), sensitivity and specificity of 75% and 96%, which performed apparently better than MRI [AUC=0.615 (95% CI: 0.480–0.750, P=0.073)]. PSMA PET-MRI showed excellent expression in the diagnosis of bone metastases, with an AUC of 0.910 (95% CI: 0.840–0.981, P <0.001) compared to 0.700 (95% CI: 0.577–0.823, P =0.001) in bone scanning. PSMA PET-MRI also had higher sensitivity than bone scanning (90% vs. 43%), while lower specificity (92% vs. 97%). Conclusion: PSMA PET-MRI is superior to conventional imaging at diagnosing metastases in lymph nodes and bones in PCa and can provide a more accurate stagement.

9 January 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
BHBiming He
Biming He
ZSZhen-Kai Shi
Zhen-Kai Shi
RCRui Chen
Rui Chen
HWHai-Feng Wang
Hai-Feng Wang
Introduction: Transurethral resection of the prostate (TURP) is the gold standard surgical treatment to lower urinary tract symptoms and benign prostatic obstruction (LUTS/BPO). Although it has been proven to have substantial efficacy in improving functional outcomes, it has shown a high incidence of complications, including transurethral resection syndrome, massive bleeding, urinary incontinence and sexual dysfunction. High-frequency irreversible electroporation (H-FIRE) is a novel non-thermal ablation technique that delivers pulsed high-voltage but low-energy electric current to the cell membrane, thereby leading to cell death. H-FIRE has been reported to be tissue-selective, which leads to fewer side effects. However, no data are available on whether H-FIRE is non-inferior compared with TURP in treating patients with LUTS/BPO regarding safety and efficacy. Methods and analysis: This trial is a prospective, single-centre, randomised controlled, double-blinded and non-inferiority study in which all men with LUTS/BPO are included. This study aims to determine whether the HI-FIRE is non-inferior to TURP for achieving better functional outcomes as measured by the co-primary outcome of the change from baseline in maximal flow rate (Q max ) and the urinary symptoms by questionnaire of International Prostate Symptom Score (IPSS) scoring at 3 months after surgical treatment. The main inclusion criteria are men with prostatic volume range 30 to 100 mL, Q max 8. A sample size of 118 participants is required, accounting for a 20% loss. All participants will be randomly allocated at a ratio of 1:1 to the H-FIRE arm (n=59) and the TURP arm (n=59). The primary outcome is to assess the change from baseline in Q max and IPSS scoring at 3 months after surgical treatment. Ethics and dissemination: Ethical approval was obtained from the ethics committee of Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. The results of the study will be disseminated and published in international peer-reviewed journals. Trial registration number: ClinicalTrials.gov: NCT05306145 .

5 February 2021 in BMJ Open
Verified
Journal Article
Open access
PDF file
BHBiming He
Biming He
RLRongbing Li
Rongbing Li
DLDongyang Li
Dongyang Li
LHLiqun Huang
Liqun Huang
XWXiaofei Wen
Xiaofei Wen
HWHaifeng Wang
Haifeng Wang
Introduction The classical pathway for diagnosing prostate cancer is systematic 12-core biopsy under the guidance of transrectal ultrasound, which tends to underdiagnose the clinically significant tumour and overdiagnose the insignificant disease. Another pathway named targeted biopsy is using multiparametric MRI to localise the tumour precisely and then obtain the samples from the suspicious lesions. Targeted biopsy, which is mainly divided into cognitive fusion method and software-based fusion method, is getting prevalent for its good performance in detecting significant cancer. However, the preferred targeted biopsy technique in detecting clinically significant prostate cancer between cognitive fusion and software-based fusion is still beyond consensus. Methods and analysis This trial is a prospective, single-centre, randomised controlled and non-inferiority study in which all men suspicious to have clinically significant prostate cancer are included. This study aims to determine whether a novel three-dimensional matrix positioning cognitive fusion-targeted biopsy is non-inferior to software-based fusion-targeted biopsy in the detection rate of clinically significant cancer in men without a prior biopsy. The main inclusion criteria are men with elevated serum prostate-specific antigen above 4–20 ng/mL or with an abnormal digital rectal examination and have never had a biopsy before. A sample size of 602 participants allowing for a 10% loss will be recruited. All patients will undergo a multiparametric MRI examination, and those who fail to be found with a suspicious lesion, with the anticipation of half of the total number, will be dropped. The remaining participants will be randomly allocated to cognitive fusion-targeted biopsy (n=137) and software-based fusion-targeted biopsy (n=137). The primary outcome is the detection rate of clinically significant prostate cancer for cognitive fusion-targeted biopsy and software-based fusion-targeted biopsy in men without a prior biopsy. The clinically significant prostate cancer will be defined as the International Society of Urological Pathology grade group 2 or higher. Ethics and dissemination Ethical approval was obtained from the ethics committee of Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. The results of the study will be disseminated and published in international peer-reviewed journals. Trial registration number ClinicalTrials.gov Registry (NCT04271527).